Robert W. Baird initiated coverage on ResMed with a new price target
$RMD
Medical/Dental Instruments
Health Care
Robert W. Baird initiated coverage of ResMed with a rating of Outperform and set a new price target of $280.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/16/2025 | $294.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 7/15/2025 | $294.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 3/19/2025 | $280.00 | Overweight | Morgan Stanley |
| 3/19/2025 | Overweight | Morgan Stanley | |
| 1/16/2025 | Buy | Goldman | |
| 1/10/2025 | $252.00 | Neutral | Piper Sandler |
| 12/13/2024 | $250.00 | Hold | Stifel |
| 9/24/2024 | $280.00 | Outperform | Robert W. Baird |
RBC Capital Mkts upgraded ResMed from Sector Perform to Outperform and set a new price target of $294.00
RBC Capital Mkts upgraded ResMed from Sector Perform to Outperform and set a new price target of $294.00
Morgan Stanley initiated coverage of ResMed with a rating of Overweight and set a new price target of $280.00
Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that board member Rich Sulpizio is thanked for two decades of contributions to Resmed, and will retire from the board, not standing for reelection at the 2025 Annual Meeting of Stockholders, scheduled fo
Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%Operating cash flow of $539 millionQuarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended June 30, 2025. Fourth Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 230 bps to 60.8%; non-GAAP gross margin improved 230 bps to 61.4
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:https://investor.resmed.com •Date:Thursday, July 31, 2025 •Time:1:30 p.m. PDT / 4:30 p.m. EDT •International:London, Thursday, July 31, 2025, 9:30 p.m. BSTSydney, Friday, August 1, 2025, 6:30 a.m. AEST Please note, Resmed
8-K - RESMED INC (0000943819) (Filer)
10-K - RESMED INC (0000943819) (Filer)
8-K - RESMED INC (0000943819) (Filer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she
Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr
NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's
Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%Operating cash flow of $539 millionQuarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended June 30, 2025. Fourth Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 230 bps to 60.8%; non-GAAP gross margin improved 230 bps to 61.4
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:https://investor.resmed.com •Date:Thursday, July 31, 2025 •Time:1:30 p.m. PDT / 4:30 p.m. EDT •International:London, Thursday, July 31, 2025, 9:30 p.m. BSTSydney, Friday, August 1, 2025, 6:30 a.m. AEST Please note, Resmed
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed's commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx's at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected wa
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)